In recent years, there have been trials suggesting that mineralocorticoid receptor antagonists, such as spironolactone, reduce the risk of cardiovascular events in patients with end-stage renal disease (ESRD) (1, 2) and chronic kidney disease (CKD) with type 2 diabetes (3). Here, NR3C2 is linked to chronic kidney disease.